A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.

A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.

2019 | JOURNAL DOI: 10.1016/J.BIOPHA.2019.108976

1-min quiz | Figure out your research career

See how Impactio can help you with your research career.

Start